Nevro Corp. reported a 40% decrease in worldwide revenue for Q2 2020, totaling $56.4 million, due to COVID-19 restrictions. U.S. revenue decreased by 35% to $51.0 million, while international revenue decreased by 65% on a constant currency basis to $5.4 million. The company experienced a net loss from operations of $35.4 million and an adjusted EBITDA of negative $22.1 million.
Worldwide revenue decreased by 40% year-over-year to $56.4 million due to COVID-19 restrictions.
U.S. revenue decreased by 35% year-over-year to $51.0 million.
International revenue decreased by 65% year-over-year to $5.4 million on a constant currency basis.
Net loss from operations increased to $35.4 million, and adjusted EBITDA was negative $22.1 million.
Despite encouraging signs of early recovery in the U.S., the company remains cautious about the visibility and predictability of its environment through the end of 2020 and is closely monitoring new pandemic developments.